MDGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Madrigal Pharmaceuticals (MDGL) is not a strong buy at this moment for a beginner, long-term investor. While the company has shown strong revenue growth and has a promising drug pipeline, the recent financial performance shows declining net income and EPS. Additionally, the stock lacks strong immediate trading signals, and analysts' ratings are mixed with some downgrades and reduced price targets. The technical indicators are neutral, and the options data does not suggest strong bullish sentiment. Therefore, holding off on buying MDGL for now is recommended.
The MACD is positive and expanding, indicating a mild bullish trend. RSI is neutral at 52.532, and moving averages are converging, showing no strong directional bias. The stock is trading near the pivot level of 431.436, with resistance at 442.216 and support at 420.656. Overall, technical indicators suggest a neutral to slightly bullish trend but lack strong momentum.
Hedge funds are significantly increasing their positions, with a 176.46% increase in buying activity last quarter.
Madrigal's FDA-approved drug, Rezdiffra, addresses a significant unmet medical need and has extended intellectual property protection until
Revenue growth of 210.77% YoY in Q4 2025 highlights strong top-line performance.
Net income dropped by 1.42% YoY, and EPS declined by 5.90% YoY in Q4 2025, reflecting profitability challenges.
Wolfe Research downgraded the stock, citing concerns about valuation and Inventiva patent strength.
Analyst price targets have been revised downward by BofA multiple times, indicating tempered expectations.
In Q4 2025, Madrigal's revenue increased by 210.77% YoY to $321.08 million, driven by the success of Rezdiffra. However, net income dropped slightly by 1.42% YoY to -$58.58 million, and EPS declined by 5.90% YoY to -2.55. Gross margin also fell by 4.43% YoY to 92.39%, indicating some pressure on profitability despite strong revenue growth.
Analyst ratings are mixed. Barclays and Citizens are optimistic, with price targets of $964 and $745, respectively, citing strong fundamentals and extended IP protection. However, Wolfe Research downgraded the stock, and BofA has reduced its price target multiple times, reflecting concerns about valuation and gross-to-net adjustments.
